menu
    • menu
    [{"orgOrder":0,"company":"EQRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"intravenous infusion","sponsorNew":"EQRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Undisclosed"},{"orgOrder":0,"company":"EQRx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EQRx \/ Cstone","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Cstone"},{"orgOrder":0,"company":"EQRx","sponsor":"CM Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"Aumolertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":2,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"Tablet","sponsorNew":"EQRx \/ CM Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ CM Life Sciences"},{"orgOrder":0,"company":"EQRx","sponsor":"Abdul Latif Jameel Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Aumolertinib","moa":"ErbB1","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Abdul Latif Jameel Health","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Abdul Latif Jameel Health"},{"orgOrder":0,"company":"EQRx","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EQRx \/ EQRx","highestDevelopmentStatusID":"4","companyTruncated":"EQRx \/ EQRx"},{"orgOrder":0,"company":"EQRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aumolertinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Not Applicable"},{"orgOrder":0,"company":"EQRx","sponsor":"Aurigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"EQRx \/ EQRx","highestDevelopmentStatusID":"2","companyTruncated":"EQRx \/ EQRx"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"}]

    Find Clinical Drug Pipeline Developments & Deals by EQRx

    Menu

    EQRx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Revolution Medicines Completes Acquisition of EQRx

                            Details : Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.

                            Brand Name : RMC-6236

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 09, 2023

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More than $1 Billion in Addi...

                            Details : Through the acquisition, Revolution expects to conduct late-stage development of RAS(ON) inhibitor drug candidate pipeline, including RMC-6236, in multiple RAS-driven cancers.

                            Brand Name : RMC-6236

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : RMC-6236

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Revolution Medicines

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Aurigene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnershi...

                            Details : Under the terms of the collaboration agreement, Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 05, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Aurigene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

                            Details : Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.

                            Brand Name : EQ143

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 29, 2022

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Insilico Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Dev...

                            Details : The collaboration will combine Insilico's Pharma.AI platform to advance de novo small molecule design and generation with EQRx's clinical development and commercialization expertise.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 24, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Insilico Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Abdul Latif Jameel Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in...

                            Details : Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

                            Brand Name : EQ143

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 22, 2021

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Abdul Latif Jameel Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : CM Life Sciences

                            Deal Size : $2,000.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III

                            Details : Proceeds expand balance sheet to ~$2.0 billion and will be used for “new pharma” platforms. EQRx’s growing pipeline includes two pre-registrational oncology assets that have shown promising Phase 3 data (aumolertinib and sugemalimab), and other cli...

                            Brand Name : EQ143

                            Molecule Type : Small molecule

                            Upfront Cash : $2,000.0 million

                            August 06, 2021

                            Lead Product(s) : Aumolertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : CM Life Sciences

                            Deal Size : $2,000.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sugemalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : CStone Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung ...

                            Details : GEMSTONE-301 study investigating sugemalimab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC without disease progression after either concurrent or sequential chemoradiotherapy.

                            Brand Name : CS1001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 28, 2021

                            Lead Product(s) : Sugemalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : CStone Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            EQRx

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sugemalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $500.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing

                            Details : Funding accelerates development of late-stage cancer therapies which includes sugemalimab, almonertinib, EQRx’s PD-1 antibody (formerly known as CS1003) and lerociclib, a CDK4/6 inhibitor.

                            Brand Name : CS1001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 11, 2021

                            Lead Product(s) : Sugemalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $500.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth